MedPath

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients

Not Applicable
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Major Depression
Interventions
Behavioral: Enhanced Care
Behavioral: Treatment Adherence Intervention
Registration Number
NCT00151372
Lead Sponsor
Weill Medical College of Cornell University
Brief Summary

Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity. This study investigates the effectiveness of a care management intervention aimed at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability at a 28-week follow-up period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
141
Inclusion Criteria
  • Chronic obstructive pulmonary disease by American Thoracic Society criteria
  • Major depression by DSM-IV criteria
  • 17-item Hamilton score >14
  • English speaking
Exclusion Criteria
  • Inability to give informed consent
  • MiniMental score <24
  • Aphasia
  • Nursing home placement after discharge

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Enhanced CareEnhanced CareIn the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team.
Treatment Adherence InterventionTreatment Adherence InterventionIn the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
Primary Outcome Measures
NameTimeMethod
Composite Antidepressant Score Scale (CAD)28 Weeks

The Composite Antidepressant Score scale (CAD) describes the adequacy of an antidepressant's dosage. Scores range from 0-4 with 0, 1, and 2 signifying subthreshold or non-adequate therapeutic dosages while 3 and 4 signify a therapeutic/adequate dosage. The best value is 4 while the worst value is 0.

Secondary Outcome Measures
NameTimeMethod
Hamilton Depression Rating Scale28 Weeks

The 17-item Hamilton Depression Rating Scale (HDRS) measures the severity of a depressive episode: the higher the score, the more severe the depression. The Best value is 0 and the Worst value is 52.

Trial Locations

Locations (3)

Helen Hayes Hospital

🇺🇸

West Haverstraw, New York, United States

Weill Medical College of Cornell University

🇺🇸

White Plains, New York, United States

Burke Rehabilitation Hospital

🇺🇸

White Plains, New York, United States

© Copyright 2025. All Rights Reserved by MedPath